-
Published 4/20/2025
Thomson SJ, Mistry R, Bayly H, Overbeck V, Sagar M, Schechter-Perkins EM, White LF, Jacobson KR, Bouton TC. Barriers to recruitment of an observational SARS-CoV-2 emergency department cohort at Boston Medical Center. BMC Emerg Med. 2025 Apr 20; 25(1):68. PMID: 40254607.
-
Published 10/23/2024
Bean DJ, Liang YM, Sagar M. Recent Endemic Coronavirus Infection Associates With Higher SARS-CoV-2 Cross-Reactive Fc Receptor Binding Antibodies. bioRxiv. 2024 Oct 23. PMID: 39484477.
-
Published 6/27/2024
Heindel DW, Figueroa Acosta DM, Goff M, Yengo CK, Jan M, Liu X, Wang XH, Petrova MI, Zhang M, Sagar M, Barnette P, Pandey S, Hessell AJ, Chan KW, Kong XP, Chen BK, Mahal LK, Bensing BA, Hioe CE. HIV-1 interaction with an O-glycan-specific bacterial lectin enhances virus infectivity and resistance to neutralizing antibodies. iScience. 2024 Aug 16; 27(8):110390. PMID: 39108723.
-
Published 6/12/2024
Bean DJ, Monroe J, Liang YM, Borberg E, Senussi Y, Swank Z, Chalise S, Walt D, Weinberg J, Sagar M. Heterotypic immunity from prior SARS-CoV-2 infection but not COVID-19 vaccination associates with lower endemic coronavirus incidence. Sci Transl Med. 2024 Jun 12; 16(751):eado7588. PMID: 38865483.
-
Published 1/3/2024
Heindel DW, Figueroa Acosta DM, Goff M, Yengo CK, Jan M, Liu X, Wang XH, Petrova MI, Zhang M, Sagar M, Barnette P, Pandey S, Hessell AJ, Chan KW, Kong XP, Chen BK, Mahal LK, Bensing BA, Hioe CE. HIV-1 interaction with an O-glycan-specific bacterial lectin enhances virus infectivity and resistance to neutralization by antibodies. Res Sq. 2024 Jan 03. PMID: 36824869.